The Role of Sphingolipids Metabolism in Cancer Drug Resistance.
acid ceramidase (AC)
cancer
glucosylceramide synthase (GCS)
shingolipids
sphingomyelinase (SMase)
sphingosine kinase 1 (SPHK1)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
11
2021
accepted:
07
12
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
11
1
2022
Statut:
epublish
Résumé
Drug resistance continues to be one of the major challenges to cure cancer. As research in this field evolves, it has been proposed that numerous bioactive molecules might be involved in the resistance of cancer cells to certain chemotherapeutics. One well-known group of lipids that play a major role in drug resistance are the sphingolipids. Sphingolipids are essential components of the lipid raft domains of the plasma membrane and this structural function is important for apoptosis and/or cell proliferation. Dysregulation of sphingolipids, including ceramide, sphingomyelin or sphingosine 1-phosphate, has been linked to drug resistance in different types of cancer, including breast, melanoma or colon cancer. Sphingolipid metabolism is complex, involving several lipid catabolism with the participation of key enzymes such as glucosylceramide synthase (GCS) and sphingosine kinase 1 (SPHK1). With an overview of the latest available data on this topic and its implications in cancer therapy, this review focuses on the main enzymes implicated in sphingolipids metabolism and their intermediate metabolites involved in cancer drug resistance.
Identifiants
pubmed: 35004331
doi: 10.3389/fonc.2021.807636
pmc: PMC8733468
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
807636Informations de copyright
Copyright © 2021 Bataller, Sánchez-García, Garcia-Mayea, Mir, Rodriguez and LLeonart.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Biol Chem. 1998 Nov 20;273(47):31621-8
pubmed: 9813079
Cancer Res. 2014 Nov 1;74(21):5937-41
pubmed: 25320006
Mol Carcinog. 2021 Dec;60(12):840-858
pubmed: 34516706
J Neurosci Res. 2004 Jan 1;75(1):66-74
pubmed: 14689449
Blood. 2011 Jun 2;117(22):5941-52
pubmed: 21527515
Int J Cancer. 2009 Dec 1;125(11):2728-36
pubmed: 19521959
Breast Cancer Res Treat. 2008 Nov;112(1):41-52
pubmed: 18058224
FEBS Lett. 2002 Oct 30;531(1):38-46
pubmed: 12401200
J Proteome Res. 2012 Feb 3;11(2):1078-88
pubmed: 22074005
Oncotarget. 2017 Nov 7;8(68):112662-112674
pubmed: 29348854
Oncotarget. 2017 Apr 11;8(15):24753-24761
pubmed: 28445970
Curr Biol. 2000 Nov 30;10(23):1527-30
pubmed: 11114522
Adv Lipid Res. 1993;26:183-213
pubmed: 8379450
Front Oncol. 2015 Feb 13;5:31
pubmed: 25763355
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Oncotarget. 2016 May 3;7(18):24995-5009
pubmed: 27107419
Int J Breast Cancer. 2013;2013:137414
pubmed: 23864953
J Biol Chem. 2005 Nov 4;280(44):37118-29
pubmed: 16118219
Mol Cancer Ther. 2004 May;3(5):633-9
pubmed: 15141021
Breast Cancer Res Treat. 2018 Nov;172(1):33-43
pubmed: 30043096
J Biol Chem. 2000 Jun 30;275(26):19513-20
pubmed: 10751414
Cell Death Differ. 2004 Aug;11(8):853-61
pubmed: 15088070
Mol Ther. 2007 Jul;15(7):1259-63
pubmed: 17426710
Mol Cancer Ther. 2006 Feb;5(2):200-8
pubmed: 16505092
Cancer Biol Ther. 2017 Jun 3;18(6):400-406
pubmed: 28494176
J Surg Oncol. 2011 Oct;104(5):466-71
pubmed: 21538359
Leuk Res. 2008 Mar;32(3):475-80
pubmed: 17709137
Biomolecules. 2020 Sep 23;10(10):
pubmed: 32977496
Biochem J. 1998 Oct 15;335 ( Pt 2):301-4
pubmed: 9761727
J Biol Chem. 2007 Apr 13;282(15):10922-34
pubmed: 17303574
Cancer Res. 2003 Sep 15;63(18):5962-9
pubmed: 14522923
J Clin Invest. 2001 Jul;108(1):143-51
pubmed: 11435466
Cell Death Dis. 2012 Dec 20;3:e449
pubmed: 23254292
Cancer Invest. 2012 Jan;30(1):27-37
pubmed: 22236187
Semin Cell Dev Biol. 2004 Oct;15(5):513-20
pubmed: 15271296
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014 Feb;31(1):34-8
pubmed: 24510559
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1284-90
pubmed: 16516161
Oncotarget. 2016 Jun 14;7(24):36755-36766
pubmed: 27191984
Cancer Res. 2009 Sep 1;69(17):6915-23
pubmed: 19723667
J Biol Chem. 2007 Jun 8;282(23):16718-28
pubmed: 17283068
FASEB J. 2001 Mar;15(3):719-30
pubmed: 11259390
J Neurochem. 2001 Mar;76(5):1573-84
pubmed: 11238741
J Surg Res. 2017 Nov;219:202-213
pubmed: 29078883
Anticancer Drugs. 2018 Jan;29(1):50-60
pubmed: 29023248
FASEB J. 2008 Jul;22(7):2541-51
pubmed: 18245173
In Vitro Cell Dev Biol Anim. 2015 Nov;51(10):1056-63
pubmed: 26170224
Cancer Biol Ther. 2007 Sep;6(9):1455-60
pubmed: 17881906
BMC Cancer. 2018 Feb 6;18(1):153
pubmed: 29409484
Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
pubmed: 18216770
Cancer Chemother Pharmacol. 2009 Oct;64(5):1053-8
pubmed: 19597728
Apoptosis. 2015 May;20(5):621-34
pubmed: 25652700
Oncotarget. 2016 Dec 13;7(50):83208-83222
pubmed: 27825124
Nat Rev Mol Cell Biol. 2003 May;4(5):397-407
pubmed: 12728273
Arch Biochem Biophys. 1994 Jun;311(2):354-7
pubmed: 8203897
J Biol Chem. 1999 Jan 8;274(2):1140-6
pubmed: 9873062
Int J Mol Sci. 2021 Jun 25;22(13):
pubmed: 34201962
J Biol Chem. 2002 Mar 22;277(12):9936-43
pubmed: 11788605
Sci Rep. 2021 May 27;11(1):11221
pubmed: 34045496
Cell Signal. 2021 Feb;78:109860
pubmed: 33271224
Antioxid Redox Signal. 2007 Sep;9(9):1449-56
pubmed: 17576160
Pharmaceuticals (Basel). 2016 Jun 16;9(2):
pubmed: 27322289
Int J Oncol. 2011 Aug;39(2):425-31
pubmed: 21617856
Mol Ther. 2009 Mar;17(3):430-8
pubmed: 19107118
Cancer Biol Ther. 2011 Apr 1;11(7):647-50
pubmed: 21307640
Expert Opin Ther Targets. 2017 Jun;21(6):583-590
pubmed: 28434262
Biochem Biophys Res Commun. 2015 Jan 16;456(3):821-6
pubmed: 25498501
PLoS One. 2017 Jun 14;12(6):e0177805
pubmed: 28614356
J Biol Chem. 2011 Aug 12;286(32):28200-9
pubmed: 21700700
Leukemia. 2006 Jan;20(1):95-102
pubmed: 16281067
Cell. 1996 Jul 26;86(2):189-99
pubmed: 8706124
Cancer Res. 2004 May 15;64(10):3593-8
pubmed: 15150117
J Biol Chem. 2004 Feb 27;279(9):7867-76
pubmed: 14662772
Exp Hematol. 2011 Jun;39(6):653-665.e6
pubmed: 21392556
Biochem Cell Biol. 2004 Feb;82(1):27-44
pubmed: 15052326
Mol Cell Biol. 2005 Dec;25(24):11113-21
pubmed: 16314531
Glycoconj J. 2000 Mar-Apr;17(3 -4):143-51
pubmed: 11201785
Chem Phys Lipids. 1999 Nov;102(1-2):65-77
pubmed: 11001562
Biochim Biophys Acta. 2015 Sep;1851(9):1134-45
pubmed: 25964209
Mol Ther. 2008 Sep;16(9):1565-71
pubmed: 18628757
Biochim Biophys Acta. 2008 Sep;1781(9):424-34
pubmed: 18619555
J Biol Chem. 2016 Jan 29;291(5):2422-34
pubmed: 26553872
Cell Mol Life Sci. 2018 Sep;75(18):3393-3410
pubmed: 29549423
J Natl Cancer Inst. 2001 Mar 7;93(5):347-57
pubmed: 11238696
Endocrinology. 2009 Oct;150(10):4484-92
pubmed: 19706837
Exp Cell Res. 2002 Nov 15;281(1):115-27
pubmed: 12441135
Front Biosci. 2008 Jan 01;13:2293-8
pubmed: 17981711
PLoS One. 2013 May 07;8(5):e63527
pubmed: 23667632
Int J Mol Sci. 2021 Aug 25;22(17):
pubmed: 34502095
Methods Enzymol. 2000;312:361-73
pubmed: 11070884
Mol Cancer. 2010 Jun 11;9:145
pubmed: 20540746
Mol Cancer Ther. 2015 Aug;14(8):1907-15
pubmed: 26063766
Apoptosis. 2015 Jul;20(7):960-74
pubmed: 25846011
Life (Basel). 2020 Sep 16;10(9):
pubmed: 32948031
Oncogene. 2019 Feb;38(8):1282-1295
pubmed: 30254208
Science. 1993 Mar 19;259(5102):1769-71
pubmed: 8456305
Oncotarget. 2016 Sep 13;7(37):60575-60592
pubmed: 27517620
J Biol Chem. 2005 Aug 19;280(33):29462-9
pubmed: 15951439
Cancer Immunol Res. 2021 May;9(5):568-582
pubmed: 33727246
Hum Pathol. 2018 Apr;74:156-163
pubmed: 29320752
Glycoconj J. 2014 Oct;31(6-7):449-59
pubmed: 25129488
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191
pubmed: 29165427
Biochim Biophys Acta. 2002 Dec 30;1585(2-3):193-201
pubmed: 12531554
J Biol Chem. 2006 Sep 1;281(35):25001-5
pubmed: 16793762
EMBO Rep. 2004 Aug;5(8):777-82
pubmed: 15289826
Biochemistry. 2001 Apr 24;40(16):4893-903
pubmed: 11305904
Biochem J. 2006 Apr 15;395(2):311-8
pubmed: 16356169
Cancer Res. 2005 Dec 15;65(24):11667-75
pubmed: 16357178
Cancer Gene Ther. 2006 Dec;13(12):1045-51
pubmed: 16763610
Exp Biol Med (Maywood). 2012 Jul;237(7):832-44
pubmed: 22859737
J Exp Med. 1994 Aug 1;180(2):525-35
pubmed: 8046331
J Clin Invest. 2013 Oct;123(10):4344-58
pubmed: 24091326
J Neuropathol Exp Neurol. 2005 Aug;64(8):695-705
pubmed: 16106218
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2016 Dec 6;7(49):80943-80956
pubmed: 27821815
Oncol Lett. 2021 Aug;22(2):581
pubmed: 34122632
J Invest Dermatol. 1998 Nov;111(5):733-8
pubmed: 9804330
Genes Chromosomes Cancer. 2000 Oct;29(2):137-46
pubmed: 10959093
Pigment Cell Melanoma Res. 2010 Dec;23(6):746-59
pubmed: 20726948
Cancer Med. 2020 May;9(9):3142-3152
pubmed: 32135040
Eukaryot Cell. 2005 Jan;4(1):178-89
pubmed: 15643073
J Biol Chem. 1995 Dec 22;270(51):30701-8
pubmed: 8530509
Cancer Biol Ther. 2011 Apr 1;11(7):678-89
pubmed: 21307639